RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerONCY presented biomarker pancreatic cancer data at AACR 2019 found the following, before going on in May 2024 to demonstrate pelareorep's ability to expand TiL in both the blood and tumor cells. "Using patient blood samples from our REO 024 study in second line pancreatic cancer, T cell receptor sequencing was performed with Adaptive Biotechnologies' immunoSEQ Assay to measure the diversity or clonality of the T cell population,'' said Dr. Rita Laeufle, CMO of Oncolytics Biotech. ''Results from this analysis demonstrate that higher clonality after one three-week cycle of treatment can identify patients likely to respond to combination treatment of pelareorep and a checkpoint inhibitor.''
https://www.accesswire.com/537346/Oncolytics-BiotechR-Presents-Biomarker-Data-in-Second-line-Pancreatic-Cancer-at-AACR
In May 2024 ONCY further elaborated on pelareorep's ability to expand TiL in both the blood and tumor cell highlightes pelareorep's MOA and potential as a backbone immunotherapy for multiple cancer indications. “Pelareorep stimulates a proinflammatory response that primes tumors for immunologic killing and also activates both innate and adaptive immune responses. Our second ASCO abstract provides additional support for pelareorep’s immunotherapeutic mechanism of action by describing its ability to stimulate the expansion of pre-existing and new TIL clones in the blood, which correlate with treatment response. These results build upon previously reported data from the AWARE-1 study in breast cancer to expand our understanding of pelareorep’s immune-based mechanism of action, and it supports further investigation of TIL expansion as a potential biomarker of clinical activity in patients treated with pelareorep.” https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-asco-abstracts-highlight-pelareoreps-potential-in-pancreatic-cancer-and-immunotherapeutic-mechanism-of-action/ "Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. "
https://oncolyticsbiotech.com/press_releases/oncolytics-provides-update-on-pancreatic-cancer-program-for-pelareorep/